NetraMark appoints Jan Sedway as senior VP of clinical science

NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) announced the appointment of Jan Sedway as Senior Vice President of Clinical Science. The artificial intelligence company focuses on clinical trial solutions for the pharmaceutical industry.

Sedway brings over 20 years of experience in clinical research and global operations. She previously served as Vice President of Clinical Development at Clario, where she led scientific innovation efforts and developed capabilities in dermatology and hematology therapeutic areas. She also held leadership positions at Parexel and Syneos Health.

Sedway holds a Bachelor of Arts in Psychology from the University of Michigan at Ann Arbor and received her Master of Arts and Doctorate of Philosophy in Psychology from the University of North Carolina at Chapel Hill.

"We are thrilled to welcome Jan to the NetraMark leadership team," said Josh Spiegel, President of NetraMark. "Her depth of expertise in clinical innovation and operational execution directly aligns with our growth strategy as we continue to drive adoption of our AI-powered solutions."

NetraMark develops artificial intelligence and machine learning solutions for the pharmaceutical industry. The company uses a topology-based algorithm to analyze patient datasets and segment diseases into different types while classifying patients for drug sensitivity and treatment efficacy.

The appointment comes as NetraMark expands its presence in psychiatry, oncology and other therapeutic areas. The information is based on a company press release statement.

You May Also Be Interested In

• Cloudastructure grows sales team by 30% to meet enterprise demand
• Molson Coors EMEA&APAC president steps back for medical leave
• Picard Medical names interim CEO after leadership change